Genomic alterations in DNA damage repair (DDR) genes are prevalent in both primary and metastatic PCa tissue [36], leading to the clinical utilisation of PARP inhibitors (PARPi) in patients with DDR deficiencies, however, the emergence of PARPi resistance has been observed [37, 38]. The gene discussed is PARP1; the disease is posterior cortical atrophy.